Apellis Pharmaceuticals Inc   (APLS)
Other Ticker:  
Price: $63.8900 $1.92 3.098%
Day's High: $65.74 Week Perf: -10.93 %
Day's Low: $ 61.52 30 Day Perf: 0.95 %
Volume (M): 2,802 52 Wk High: $ 94.75
Volume (M$): $ 178,988 52 Wk Avg: $61.47
Open: $62.86 52 Wk Low: $19.83

 Market Capitalization (Millions $) 7,658
 Shares Outstanding (Millions) 120
 Employees -
 Revenues (TTM) (Millions $) 273
 Net Income (TTM) (Millions $) -606
 Cash Flow (TTM) (Millions $) -132
 Capital Exp. (TTM) (Millions $) 2

Apellis Pharmaceuticals Inc
Apellis Pharmaceuticals Inc is a biopharmaceutical company that focuses on discovering, developing, and commercializing novel therapeutics to treat a wide range of diseases. The company is mainly focused on targeting the complement system, which is a part of the immune system responsible for regulating inflammation and immune response.

Apellis Pharmaceuticals has developed a platform called the PEGylation technology, which helps in optimizing the pharmacokinetics and pharmacodynamics of therapeutic compounds. The company's lead product candidate, pegcetacoplan, is being developed for several complement-driven diseases, including paroxysmal nocturnal hemoglobinuria (PNH), geographic atrophy (GA), and C3 glomerulopathy (C3G).

The company's goal is to address unmet medical needs by developing innovative therapies that can provide a significant impact on patients' lives. Apellis Pharmaceuticals is dedicated to advancing its product pipeline through rigorous research and clinical trials, and ultimately, to commercialize its investigational therapies for the benefit of patients worldwide.

   Company Address: 100 Fifth Avenue Waltham 2451 MA
   Company Phone Number: 977-5700   Stock Exchange / Ticker: NASDAQ APLS


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Management Announcement

Apellis Pharmaceuticals Faces Obstacles as CHMP Gives Negative Opinion on Pegcetacoplan for GA Treatment in EU; Planned Re-Examination to Determine Future

Published Fri, Jan 26 2024 12:06 PM UTC

Date: Today's Date
WALTHAM, Mass. - Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) received a blow to its plans for the marketing authorization of intravitreal pegcetacoplan in the European Union (EU) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The Committee for Medicinal Products for Human Use (CHMP) of th...

Product Service News

Apellis Pharmaceuticals: Revolutionizing Revenue and Patient Care

Published Mon, Jan 8 2024 2:00 PM UTC

Apellis Pharmaceuticals, Inc., a leading biopharmaceutical company, recently announced its preliminary fourth-quarter and full-year net product revenues for 2023. The figures reveal significant success in the sales of its flagship drugs, SYFOVRE and EMPAVELI. Furthermore, the company witnessed an extraordinary revenue increase of 400.54% year on year and a sequential growth ...

Stock Market Announcement

Apellis Pharmaceuticals Bolsters Workforce with Strategic Equity Inducement Grants

Published Fri, Jan 5 2024 9:05 PM UTC

Apellis Pharmaceuticals recently made an exciting announcement regarding the approval of equity awards for two new employees. These inducement grants, made in accordance with Nasdaq Listing Rule 5635(c)(4), were designed to be material incentives for their acceptance of employment with the company. The awards, issued outside of the 2017 Stock Incentive Plan but und...

Stock Market Announcement

Apellis Pharmaceuticals Attracts Top Talent and Soars in Share Performance with Inducement Grants

Published Wed, Dec 6 2023 9:05 PM UTC

Apellis Pharmaceuticals Approves Inducement Grants for New Employees, Impacts Share Performance
Apellis Pharmaceuticals, a leading biopharmaceutical company, recently announced the approval of equity awards for four new employees outside of their existing stock incentive plan. According to the company's press release, these grants were made under Nasdaq Listing Rule 5635...


Apellis Pharmaceuticals Supercharges Workforce with Equity Inducement Awards: Unleashing Potential for Company Shares

Published Mon, Nov 6 2023 9:06 PM UTC

Apellis Pharmaceuticals Bolsters Workforce with Equity Inducement Awards: What It Means for Company Shares
WALTHAM, Mass., Nov. 06, 2023 - Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) has recently announced the approval of equity awards granted to 20 new employees, effective from November 1, 2023. These awards have been offered as equity inducement awards outside of the ...


Apellis Pharmaceuticals Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com